@article {4536,
	title = {Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers.},
	journal = {Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology// Indian J Gastroenterol},
	volume = {32},
	year = {2013},
	note = {Comment in: Indian J Gastroenterol. 2013 Sep;32(5):289-90; PMID: 23873607},
	month = {2013//},
	pages = {291 - 6},
	address = {India},
	abstract = {BACKGROUND: Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source., AIMS: This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients., MATERIAL AND METHODS: Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA., RESULTS: Twenty of 3,600 (0.56 \%) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 \%) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 \%) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained., CONCLUSION: Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.},
	keywords = {*Blood Transfusion/ae [Adverse Effects], *Hepatitis B/ep [Epidemiology], *Neoplasms/th [Therapy], Adolescent, Adult, Aged, Blood Safety, Child, DNA, Viral/bl [Blood], Female, Hepatitis B Surface Antigens/bl [Blood], Hepatitis B virus/ge [Genetics], Hepatitis B virus/im [Immunology], Hepatitis B/im [Immunology], Hepatitis B/tm [Transmission], Humans, Incidence, India/ep [Epidemiology], Male, Middle Aged, Seroepidemiologic Studies, Young Adult},
	isbn = {0975-0711},
	author = {Sodhi, Jaswinder Singh and Wani, Nayeem and Jeelani, Samoon and Geelani, Sajad and Akhtar, Fehmida and Javid, Gul and Yattoo, Gh Nabi and Shah, Altaf and Gulzar, Gh Mohd and Khan, Mushtaq A and Parveen, Shaheena and Saif, Riyaz-U and Showkat, Abid}
}
